We found that YAP1 expression was associated with high immune score, high stromal score, high tumor heterogeneity, and decreased infiltration of plasma cells and follicular helper T cells, indicating that remodeling the immune microenvironment might guarantee clinical benefits in SCLC patients with high YAP1 expression. Here, YAP1 is linked to neoplasm.